: A study assessing the prevalence of risk factors (hypertension, overweight, etc.) in patients with Myotonic Dystrophy Type 1 (DM1) . Gastroenterology :
Research on the effectiveness of the drug for inducing remission in Inflammatory Bowel Disease.
The label "P397" is frequently used as a poster or abstract identifier at major medical conferences. Some of the most notable reports under this tag include: : A study assessing the prevalence of risk
In the UK energy market, refers to a specific modification proposal within the Balancing and Settlement Code (BSC) .
A study on predicting the risk of intraepithelial neoplasia in patients with longstanding . Genetic Disorders : Some of the most notable reports under this
: For further details, the Elexon P397 Modification Page provides the final modification reports and consultation history. 2. Medical and Scientific Research
: It was formally approved by the energy regulator, Ofgem , in October 2020 and implemented on October 12, 2020 . : A study assessing the prevalence of risk
A report expanding the phenotypic spectrum of , focusing on neurodevelopmental traits like ADHD and autism.